Daptomycin
| Clinical data | |
|---|---|
| Trade names | Cubicin, Cubicin RF, Dapzura RT | 
| Other names | LY 146032 | 
| AHFS/Drugs.com | Monograph | 
| License data | 
 | 
| Pregnancy category | 
 | 
| Routes of administration | Intravenous | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | n/a | 
| Protein binding | 90–95% | 
| Elimination half-life | 7–11 hours (up to 28 hours in renal impairment) | 
| Excretion | Kidney (78%; primarily as unchanged drug); faeces (5.7%) | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.116.065 | 
| Chemical and physical data | |
| Formula | C72H101N17O26 | 
| Molar mass | 1620.693 g·mol−1 | 
| 
 | |
| (what is this?) (verify) | |
| Daptomycin | |
|---|---|
| 1. Daptomycin binds and inserts into the cell membrane. 2. It aggregates in the membrane. 3. It alters the shape of the membrane to form a hole, allowing ions in and out of the cell easily. | |
| Identifiers | |
| Symbol | N/A | 
| TCDB | 1.D.15 | 
| OPM superfamily | 163 | 
| OPM protein | 1t5n | 
Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.
Daptomycin was removed from the World Health Organization's List of Essential Medicines in 2019. The World Health Organization classifies daptomycin as critically important for human medicine.